Cargando…

TRIM21—From Intracellular Immunity to Therapy

Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell me...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Stian, Bottermann, Maria, Jonsson, Alexandra, Sandlie, Inger, James, Leo C., Andersen, Jan Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722209/
https://www.ncbi.nlm.nih.gov/pubmed/31555278
http://dx.doi.org/10.3389/fimmu.2019.02049
_version_ 1783448486096666624
author Foss, Stian
Bottermann, Maria
Jonsson, Alexandra
Sandlie, Inger
James, Leo C.
Andersen, Jan Terje
author_facet Foss, Stian
Bottermann, Maria
Jonsson, Alexandra
Sandlie, Inger
James, Leo C.
Andersen, Jan Terje
author_sort Foss, Stian
collection PubMed
description Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell membrane. Upon engagement of the Fc of antibodies bound to viruses, TRIM21 triggers a coordinated effector and signaling response that prevents viral replication while at the same time inducing an anti-viral cellular state. This dual effector function is tightly regulated by auto-ubiquitination and phosphorylation. Therapeutically, TRIM21 has been shown to be detrimental in adenovirus based gene therapy, while it may be favorably utilized to prevent tau aggregation in neurodegenerative disorders. In addition, TRIM21 may synergize with the complement system to block viral replication as well as transgene expression. TRIM21 can also be utilized as a research tool to deplete specific proteins in cells and zebrafish embryos. Here, we review our current biological understanding of TRIM21 in light of its versatile functions.
format Online
Article
Text
id pubmed-6722209
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67222092019-09-25 TRIM21—From Intracellular Immunity to Therapy Foss, Stian Bottermann, Maria Jonsson, Alexandra Sandlie, Inger James, Leo C. Andersen, Jan Terje Front Immunol Immunology Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell membrane. Upon engagement of the Fc of antibodies bound to viruses, TRIM21 triggers a coordinated effector and signaling response that prevents viral replication while at the same time inducing an anti-viral cellular state. This dual effector function is tightly regulated by auto-ubiquitination and phosphorylation. Therapeutically, TRIM21 has been shown to be detrimental in adenovirus based gene therapy, while it may be favorably utilized to prevent tau aggregation in neurodegenerative disorders. In addition, TRIM21 may synergize with the complement system to block viral replication as well as transgene expression. TRIM21 can also be utilized as a research tool to deplete specific proteins in cells and zebrafish embryos. Here, we review our current biological understanding of TRIM21 in light of its versatile functions. Frontiers Media S.A. 2019-08-28 /pmc/articles/PMC6722209/ /pubmed/31555278 http://dx.doi.org/10.3389/fimmu.2019.02049 Text en Copyright © 2019 Foss, Bottermann, Jonsson, Sandlie, James and Andersen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Foss, Stian
Bottermann, Maria
Jonsson, Alexandra
Sandlie, Inger
James, Leo C.
Andersen, Jan Terje
TRIM21—From Intracellular Immunity to Therapy
title TRIM21—From Intracellular Immunity to Therapy
title_full TRIM21—From Intracellular Immunity to Therapy
title_fullStr TRIM21—From Intracellular Immunity to Therapy
title_full_unstemmed TRIM21—From Intracellular Immunity to Therapy
title_short TRIM21—From Intracellular Immunity to Therapy
title_sort trim21—from intracellular immunity to therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722209/
https://www.ncbi.nlm.nih.gov/pubmed/31555278
http://dx.doi.org/10.3389/fimmu.2019.02049
work_keys_str_mv AT fossstian trim21fromintracellularimmunitytotherapy
AT bottermannmaria trim21fromintracellularimmunitytotherapy
AT jonssonalexandra trim21fromintracellularimmunitytotherapy
AT sandlieinger trim21fromintracellularimmunitytotherapy
AT jamesleoc trim21fromintracellularimmunitytotherapy
AT andersenjanterje trim21fromintracellularimmunitytotherapy